Why 19% fewer Black patients and 9% fewer Latino patients getting GLP-1s is not a clinical issue — it’s a system failure

GLP-1 therapies are on track to become one of the largest categories in modern healthcare.

But here’s the uncomfortable truth:

The biggest growth constraint is not demand.
It’s access design.

Black patients are 19% less likely to receive GLP-1 prescriptions.
Latino patients are 9% less likely.

That is not just an equity gap.

👉 It is a multi-billion dollar market inefficiency.

And more importantly:

👉 It reveals why most GLP-1 strategies will fail to scale.

🧠 The Core Misconception: GLP-1 ≠ Prescription Funnel

Most companies approach GLP-1 as:

→ marketing → telehealth → prescription → revenue

That model breaks quickly.

Why?

Because healthcare buyers don’t underwrite prescriptions.
They underwrite systems.

Employers, payers, and investors are asking:

• Will patients stay on therapy?
• Will outcomes improve?
• Will costs go down?
• Will access expand equitably?
• Will adherence hold at scale?

If the answer is unclear → no reimbursement, no scale, no leverage

⚙️ The Real Game: Building the GLP-1 Access System

From what I see across the US ecosystem, the winners are not single-layer companies.

They are building multi-layer systems across six critical engines:

1️⃣ Digital Access Engine (Demand → Entry)

Players:
Ro, Hims & Hers, Noom Med, Found, Calibrate, Sesame, Teladoc, LifeMD, Henry Meds, Midi Health

Role:

• Reduce friction to entry
• Capture demand early
• Enable virtual prescribing pathways

Gap:
High acquisition. Low long-term retention without deeper systems.

2️⃣ Payer & Coverage Engine (Affordability → Scale)

Players:
Capital Rx, SmithRx, Navitus, Rightway, Omada, Accolade, Transcarent, Elevance Health, Blue Cross NC, KFF, ICER

Role:

• Determine access through coverage
• Define reimbursement logic
• Control cost containment

Reality:
If you’re not aligned with this layer → you don’t scale.

3️⃣ Clinical Delivery Engine (Prescription → Outcomes)

Players:
Obesity Medicine Association, Enara Health, Intellihealth, 9amHealth, Alfie Health, Cleveland Clinic, NYU Langone, UCSF, Mayo Clinic

Role:

• Deliver care beyond prescription
• Manage comorbidities
• Ensure clinical oversight

Investor lens:
Outcomes > prescriptions.

4️⃣ Retention & Lifestyle Engine (Adherence → ROI)

Players:
Noom, Foodsmart, Virta Health, Cecelia Health, DarioHealth, Solera, WW, Wondr Health, Lark, Headspace

Role:

• Drive adherence
• Support behavioral change
• Reduce drop-off rates

Critical insight:
GLP-1 dropout rates can exceed 50% within 12 months.

This is where value is won or lost.

5️⃣ Equity Access Engine (Reach → Expansion)

Players:
Obesity Action Coalition, Black Women’s Health Imperative, NHMA, Association of Black Cardiologists, NMA, Families USA, UnidosUS, NMQF

Role:

• Expand access across underserved populations
• Build trust and engagement
• Unlock new patient segments

Why it matters:
Equity is not just ethics.

👉 It is market expansion + revenue growth

6️⃣ Evidence & Policy Engine (Validation → Adoption)

Players:
CMS, FDA, NIH NIDDK, CDC, American Heart Association, Commonwealth Fund, RWJF, PHTI, GoodRx, Novo Nordisk, Eli Lilly

Role:

• Define guidelines
• Shape reimbursement policy
• Influence prescribing behavior

Truth:
No evidence → no scale.

📉 Where Most GLP-1 Companies Fail

Across dozens of founders and teams I’ve worked with, the same pattern shows up:

They optimize for:
→ acquisition
→ prescriptions
→ short-term revenue

But ignore:
→ adherence
→ payer logic
→ long-term outcomes
→ system integration

Result:

❌ High CAC
❌ Low retention
❌ Weak reimbursement
❌ Limited partnerships
❌ Fragile investor narrative

📈 Where the Real ROI Sits

The upside is massive — but only if you build across the system.

A strong GLP-1 strategy unlocks:

→ Higher conversion rates (better access design)
→ Lower churn (retention engine)
→ Stronger payer conversations (coverage alignment)
→ Better clinical outcomes (delivery + adherence)
→ Expanded TAM (equity layer)
→ Premium valuation (system vs product)

This is what investors are underwriting.

Not your funnel.

👉 Your system architecture

🧩 The GrowthVybz Framework

This is how I structure GLP-1 / obesity care growth systems:

1. Access Engine

How patients enter the system

2. Coverage Engine

How care gets paid for

3. Clinical Engine

How outcomes are delivered

4. Retention Engine

How patients stay engaged

5. Equity Engine

How markets expand

6. Evidence Engine

How trust and scale are unlocked

If one layer is weak → growth leaks.

⚡ The Strategic Shift

The companies that win this market will not be:

→ the cheapest
→ the fastest growing
→ the most visible

They will be:

👉 the most systemically integrated

🚀 What Founders, Executives & Investors Should Do Now

Founders

• Stop pitching GLP-1 as a product
• Start positioning it as a system

Executives

• Align commercial, clinical and payer strategy
• Measure outcomes, not prescriptions

Investors

• Evaluate companies on system depth
• Not just top-line growth

📊 What I Built (For You)

To make this actionable, I created:

✔️ A GLP-1 Access & Obesity Equity Market Map
(100+ organizations across all 6 layers)

✔️ A diagnostic tool
to identify where your strategy is leaking growth

✔️ A system framework
to reposition your company for scale